Synacthen Depot (cosyntropin) / Mallinckrodt, Alliance, Novartis  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Synacthen Depot (cosyntropin) / Novartis, Mallinckrodt, Alliance
2012-001682-33: Rescue of Addison’s disease 2

Ongoing
2
30
Europe
Mabthera Infusion, Solu-Medrone, Synacthen Depot, Rituximab, Methylprednisolone, Tetracosactide acetate, Mabthera infusion, Solu-Medrone, Synacthen Depot, Mabthera infusion, Solu-Medrone, Synacthen Depot
Newcastle upon Tyne Hospitals NHS Foundation Trust, Medical Research Council
Autoimmune Addison\'s disease: autoimmune primary adrenal insufficiency
 
 
ESYBRECHE, NCT02813655 / 2015-003357-17: Evaluation of the Effectiveness and Tolerance of Tetracosactide Synacthen® in the Treatment of Post Dural Puncture Headaches

Terminated
2
46
Europe
Tetracosactide (Synacthène®), placebo saline (0.9% NaCl)
Hospices Civils de Lyon
Post-dural Puncture Headache
11/22
11/22
NeSST2, NCT03514589: The Development of a Noninvasive Short Synacthen Test

Recruiting
2
12
Europe
nasal Tetracosactide, cosyntropin, Synacthen, IV tetracosactide, synacthen
Sheffield Children's NHS Foundation Trust
Adrenal Suppression
12/25
12/25

Download Options